Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | BRS3 | P32247 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL948426 | 0.82 | RNASEH1 (0.49) | FFAR1BRS3CES1 | |
| SCHEMBL948656 | 0.74 | HCAR2 (0.49) | HRH3 | |
| SCHEMBL22777750 | 0.73 | MCL1 (0.49) | FFAR1 | |
| SCHEMBL4822610 | 0.73 | GSK3B (0.51) | HRH4HRH3 | |
| SCHEMBL951471 | 0.72 | DAO (0.45) | FFAR1HDAC1 | |
| SCHEMBL10076277 | 0.72 | MMP1 (0.59) | FFAR1HDAC2HDAC1 | |
| Ammonia Solution, Strong SCHEMBL27564877 | 0.72 | GSK3B (0.50) | HRH4HRH3 | |
| SCHEMBL11119674 | 0.71 | HTR7 (0.36) | HRH4HRH3 | |
| SCHEMBL9826765 | 0.69 | HTR2A (0.62) | FFAR1HDAC2HDAC1MMP12 | |
| SCHEMBL1080850 | 0.69 | PIN1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651413-B1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT (HU) | 2017-11-22 | — | — | EP | disclosed |
| US-9487462-B2 | Inhibitors of matrix metalloproteinases | PHARMAHUNGARY 2000 KFT. (HU) | 2016-11-08 | — | — | US | disclosed |
| US-9487462-B2 | Inhibitors of matrix metalloproteinases | PHARMAHUNGARY 2000 KFT. (HU) | 2016-11-08 | — | — | US | disclosed |
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TARGETEX KFT. (HU) | 2013-11-14 | — | — | US | disclosed |
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TARGETEX KFT. (HU) | 2013-11-14 | — | — | US | disclosed |
| WO-2012080762-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | PHARMAHUNGARY 2000 KFT. (HU) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303572-A1 | NOVEL INHIBITORS OF MATRIX METALLOPROTEINASES | TIMP3, MMP3, MMP13 | FFAR1 1443/4885HDAC2 297/4885HDAC1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.